Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quarterly results round-up: Grifols and Masimo grow but more woe for Tengion

This article was originally published in Clinica

Executive Summary

Spanish biosciences group Grifols saw its top line grow 30% during its first fiscal half, to €635.3m ($913.3m), boosted by its acquisition of US blood products company Talecris Biotherapeutics. Revenues from Talecris were included in Grifols’ figures from June, and helped increase sales in its bioscience division by 37% to €521.5m. Diagnostics sales were up 4% to €56.8m, and hospital revenues grew 9% to €49.3m.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel